- Type Natriuretic Peptide at resentation and Prognosis in Patients ith ST-Segment Elevation Myocardial Infarction n ENTIRE – TIMI-23 Substudy essica

OBJECTIVES We sought to evaluate B-type natriuretic peptide (BNP), alone and in comparison to cardiac troponin I (cTnI) and high-sensitivity C-reactive protein (hs-CRP), for risk assessment at initial presentation with ST-segment elevation myocardial infarction (STEMI). BACKGROUND Elevated levels of BNP drawn two to four days after acute myocardial infarction are associated with higher mortality. Sparse data are available on its use at first presentation with STEMI. METHODS We obtained samples from 438 patients presenting within 6 h of STEMI enrolled in the Enoxaparin Tenecteplase-Tissue-Type Plasminogen Activator With or Without Glycoprotein IIb/IIIa Inhibitor as Reperfusion Strategy in ST-Segment Elevation Myocardial Infarction (ENTIRE)–Thrombolysis In Myocardial Infarction (TIMI)-23 trial. Outcomes were assessed through 30 days. RESULTS Median BNP was higher in patients who died (89 pg/ml, 25th to 75th percentile: 40 to 192), compared with survivors (15 pg/ml, 25th to 75th percentile: 8.8 to 32, p 0.0001). Patients with BNP 80 pg/ml were at significantly higher risk of death (17.4% vs. 1.8%, p 0.0001). Cardiac troponin established a gradient of mortality between the highest and lowest quartile (7.9% vs. 0%, p 0.007). C-reactive protein was not associated with outcome. After adjustment for cTnI, hs-CRP, and major clinical predictors, including age, heart failure, anterior myocardial infarction location, heart rate, and blood pressure, a BNP level 80 pg/ml was associated with a seven-fold higher mortality risk (odds ratio 7.2, 95% confidence interval 2.1 to 24.5, p 0.001). Patients with BNP 80 pg/ml were also more likely to have impaired coronary flow (p 0.049) and incomplete resolution of ST-segment elevation (p 0.05). CONCLUSIONS Increased concentrations of BNP at initial presentation of patients with STEMI are associated with impaired reperfusion after fibrinolysis and higher short-term risk of mortality. These data support the value of combining markers of hemodynamic stress with traditional approaches to risk assessment in acute myocardial infarction. (J Am Coll Cardiol 2004;44: 335–9) © 2004 by the American College of Cardiology Foundation

[1]  M. Drazner,et al.  B-type natriuretic peptide in cardiovascular disease , 2003, The Lancet.

[2]  C. Frampton,et al.  B-Type Natriuretic Peptides and Ejection Fraction for Prognosis After Myocardial Infarction , 2003, Circulation.

[3]  M. Sabatine,et al.  Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. , 2003, Journal of the American College of Cardiology.

[4]  E. Braunwald,et al.  ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. , 2001, Journal of the American College of Cardiology.

[5]  M. Sabatine,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.

[6]  D. Barnett,et al.  Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. , 2000, European heart journal.

[7]  E. Antman,et al.  Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy. , 2000, Clinical chemistry.

[8]  R. Califf,et al.  Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. , 1999, The American journal of cardiology.

[9]  J G Turner,et al.  Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction , 1999, Heart.

[10]  E. Antman,et al.  C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy , 1998 .

[11]  C. Frampton,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. , 1998, Circulation.

[12]  S. Ogawa,et al.  C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. , 1997, Circulation.

[13]  N. Arakawa,et al.  Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. , 1996, Journal of the American College of Cardiology.

[14]  R. T. Lie,et al.  Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. , 1996, Circulation.

[15]  K. Nakao,et al.  Increased Plasma Levels of Brain Natriuretic Peptide in Patients With Acute Myocardial Infarction , 1993, Circulation.

[16]  A. Struthers,et al.  Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction , 1993, The Lancet.

[17]  D. Muthu,et al.  Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure , 2009 .